You are here: Industry Insights > Vaxzevria

News List

AstraZeneca revenues soar with nearly $4bn in Covid-19 vaccine sales Pharmaceutical-Technology
February 11, 2022
The drugmaker, which is just beginning to profit from its Covid-19 vaccine, has recorded $37.4bn in revenue.
New Vaxzevria data further support its use as third dose booster WorldPharmaNews
January 14, 2022
Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a third dose booster...
New study finds AstraZeneca booster generates higher antibodies against Omicron pharmatimes
January 13, 2022
AstraZeneca (AZ) has reported preliminary data from a trial it conducted on its COVID-19 booster shot, Vaxzevria.
AstraZeneca’s Vaccine, Dumped by the West, Helps Fill Gaping Need in Rest of World FirstWordPharma
December 27, 2021
AstraZeneca's COVID-19 vaccine Vaxzevria in not authorised in the US, and other countries such as Canada, Australia and those in Western Europe have shunned it after production problems
Vaxzevria significantly boosted antibody levels against Omicron WorldPharmaNews
December 24, 2021
AstraZeneca's Vaxzevria (ChAdOx1-S [Recombinant]) significantly boosted levels of antibodies against the Omicron SARS-CoV-2 variant (B.1.1.529) following a third dose booster, according to data from a new laboratory study.(1)
Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights, August 2021 europeanpharmaceuticalreview
August 10, 2021
The EMA’s drug safety committee (PRAC) recommends updating risks of Janssen COVID-19 Vaccine, though the benefit-risk balance remains unchanged.
Vaxzevria is Highly Effective After One Dose Against Severe Disease or Hospitalisation Caused by Beta and Delta Variants of Concern drugs
July 30, 2021
Real-world data from Canada showed 82% and 87% effectiveness after one dose against hospitalisation or death caused by Beta/Gamma and Delta variants respectively.
Vaxzevria has similar safety profile to mRNA COVID-19 vaccines, finds study europeanpharmaceuticalreview
July 29, 2021
New studies show rates of blood clots were similar following vaccination with Vaxzevria and Comirnaty®, plus rates of rare blood clots are lower after the second Vaxzevria dose.
Study shows AZ’s COVID-19 jab did not increase the rate of rare blood clots after second dose pharmatimes
July 29, 2021
AstraZeneca’s COVID-19 vaccine – Vaxzevria – did not increase the rate of rare blood clots with low platelets after the second dose, according to a new study.
Vaxzevria and mRNA COVID-19 Vaccines Show Similar Safety Profiles americanpharmaceuticalreview
July 29, 2021
In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with ...

Previous page 1 2 3 Next page